ZA200807767B - Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient - Google Patents
Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredientInfo
- Publication number
- ZA200807767B ZA200807767B ZA200807767A ZA200807767A ZA200807767B ZA 200807767 B ZA200807767 B ZA 200807767B ZA 200807767 A ZA200807767 A ZA 200807767A ZA 200807767 A ZA200807767 A ZA 200807767A ZA 200807767 B ZA200807767 B ZA 200807767B
- Authority
- ZA
- South Africa
- Prior art keywords
- derivative
- active ingredient
- pharmaceutical agent
- nitrogenated heterocyclic
- heterocyclic derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006066451 | 2006-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200807767B true ZA200807767B (en) | 2009-08-26 |
Family
ID=38509460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200807767A ZA200807767B (en) | 2006-03-10 | 2008-09-09 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
Country Status (15)
Country | Link |
---|---|
US (1) | US8003642B2 (es) |
EP (1) | EP1995246A4 (es) |
JP (1) | JPWO2007105637A1 (es) |
KR (1) | KR20090008217A (es) |
CN (1) | CN101443322A (es) |
AU (1) | AU2007225836A1 (es) |
BR (1) | BRPI0708731A2 (es) |
CA (1) | CA2644368A1 (es) |
EA (1) | EA200870344A1 (es) |
MA (1) | MA30294B1 (es) |
MX (1) | MX2008011414A (es) |
NO (1) | NO20083813L (es) |
RU (1) | RU2008140144A (es) |
WO (1) | WO2007105637A1 (es) |
ZA (1) | ZA200807767B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
TWI400232B (zh) * | 2004-09-13 | 2013-07-01 | Ono Pharmaceutical Co | 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑 |
NZ575514A (en) | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
AU2007225836A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
CL2007003061A1 (es) | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
EP2120928A2 (en) * | 2007-02-15 | 2009-11-25 | Pfizer Limited | Pharmaceutical compositions and methods for ccr5 antagonists |
LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
ES2445199T3 (es) | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
US8536169B2 (en) | 2008-06-05 | 2013-09-17 | Glaxo Group Limited | Compounds |
EP2324028A2 (en) | 2008-08-04 | 2011-05-25 | AstraZeneca AB | Therapeutic agents 414 |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
GB0902406D0 (en) | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
ES2542551T3 (es) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas |
AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
AR076221A1 (es) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
SI2899191T1 (sl) | 2009-04-30 | 2017-11-30 | Glaxo Group Limited | Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji |
MY161416A (en) | 2009-05-22 | 2017-04-14 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors |
JP5775070B2 (ja) * | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
US9249145B2 (en) * | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
AR081315A1 (es) * | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
ME02445B (me) | 2010-05-21 | 2016-09-20 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
DK2683643T3 (da) | 2011-03-09 | 2019-08-12 | Richard G Pestell | Prostatacancercellelinjer, gensignaturer og anvendelser deraf |
US8975235B2 (en) | 2011-03-20 | 2015-03-10 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2873743C (en) | 2012-05-14 | 2022-12-06 | Prostagene, Llc | Using modulators of ccr5 for treating cancer |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
CA3178452A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
JP6026024B2 (ja) | 2013-06-27 | 2016-11-16 | ファイザー・インク | 複素芳香族化合物およびそのドーパミンd1リガンドとしての使用 |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
EA028819B1 (ru) | 2013-10-25 | 2018-01-31 | Новартис Аг | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
ES2881228T3 (es) * | 2015-02-16 | 2021-11-29 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de los mismos |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
EP3936192A4 (en) | 2019-03-06 | 2022-11-16 | Daiichi Sankyo Company, Limited | PYRROLOPYRAZOL DERIVATIVES |
CN110590748A (zh) * | 2019-10-03 | 2019-12-20 | 黄泳华 | 芳香基氨基苄基哌嗪氮氧化物及其组合物与用途 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1063744A (en) * | 1964-05-25 | 1967-03-30 | American Cyanamid Co | 4-substituted-4'-tertiary aminoalkoxy biphenyls |
US5169855A (en) * | 1990-03-28 | 1992-12-08 | Du Pont Merck Pharmaceutical Company | Piperidine ether derivatives as psychotropic drugs or plant fungicides |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
IL118469A (en) | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
ES2217404T3 (es) | 1996-03-28 | 2004-11-01 | Glaxo Group Limited | Derivados de pirrolopirrolona como inhibidores de la elastasa de neutrofilos. |
WO1998025605A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
CA2275602C (en) | 1996-12-19 | 2003-07-22 | Hoechst Marion Roussel, Inc. | Novel carboxy substituted cyclic carboxamide derivatives |
ZA985542B (en) | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
EP1020445B1 (en) | 1997-10-02 | 2008-08-13 | Eisai R&D Management Co., Ltd. | Fused pyridine derivatives |
AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
AU1504599A (en) | 1997-12-17 | 1999-07-05 | Shionogi & Co., Ltd. | Novel pyridine compounds |
WO1999032100A2 (en) | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
JP2002501898A (ja) | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
CA2329777A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
EP1073434A1 (en) | 1998-04-27 | 2001-02-07 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000004003A1 (en) | 1998-07-14 | 2000-01-27 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
BR9912406A (pt) | 1998-07-28 | 2001-04-24 | Smithkline Beecham Corp | Compostos de anilida substituida e métodos |
US6399656B1 (en) | 1998-07-28 | 2002-06-04 | Smithkline Beecham Corporation | Compounds and methods |
WO2000010965A2 (en) * | 1998-08-20 | 2000-03-02 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use as anti-hiv agents |
WO2000010653A1 (en) | 1998-08-24 | 2000-03-02 | Orlimar Golf Equipment Company, Llc | Iron golf club head and club |
WO2000021916A1 (fr) | 1998-10-15 | 2000-04-20 | Takeda Chemical Industries, Ltd. | Procede de preparation de derives d'amine |
WO2000027800A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
CN1163484C (zh) | 1998-11-17 | 2004-08-25 | 霍夫曼-拉罗奇有限公司 | 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ |
CA2350903A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives-ccr-3 receptor antagonists |
TR200101397T2 (tr) | 1998-11-20 | 2001-11-21 | F.Hoffmann-La Roche Ag | Piperidin CCR-3 reseptörü antagonistleri |
WO2000034278A1 (fr) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Derives triazolo, et inhibiteurs de chimiokines contenant ces derives comme ingredient actif |
EP1156807A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
EP1140087A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
EP1140086A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
CA2347912A1 (en) | 1998-12-18 | 2000-06-22 | Soo S. Ko | Heterocyclic piperidines as modulators of chemokine receptor activity |
KR20010101287A (ko) | 1998-12-18 | 2001-11-14 | 블레어 큐. 퍼거슨 | 케모킨 수용체 활성의 조절자로서 n-우레이도알킬-피페리딘 |
AU2056700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
DE69926919D1 (de) | 1998-12-18 | 2005-09-29 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
CA2353635A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
US7217714B1 (en) | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
EP1140072B1 (en) | 1998-12-30 | 2004-04-14 | Smithkline Beecham Corporation | Compounds and methods |
MXPA01007033A (es) | 1999-01-13 | 2003-07-21 | Millennium Pharm Inc | Heterociclos funcionalizados como moduladores de receptores de quimiocinas. |
WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
AU3215500A (en) | 1999-01-25 | 2000-08-07 | Smithkline Beecham Corporation | Compounds and methods |
GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
JP2000309598A (ja) | 1999-02-25 | 2000-11-07 | Takeda Chem Ind Ltd | 多剤結合型新規化合物、その製造法および用途 |
US6489354B1 (en) | 1999-03-02 | 2002-12-03 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
US6362201B1 (en) | 1999-03-02 | 2002-03-26 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
US6372764B1 (en) | 1999-03-02 | 2002-04-16 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
WO2000051608A1 (en) | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
AU3521400A (en) | 1999-03-10 | 2000-09-28 | Smithkline Beecham Corporation | Compounds and methods |
AU2942000A (en) | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
NZ514709A (en) | 1999-03-24 | 2003-03-28 | Anormed Inc | Heterocyclic substituted 1,4-benzene dimethanamine derivatives useful for treating disorders mediated by chemokine receptor binding or associated with an abnormal immune response |
CN1344266A (zh) | 1999-03-26 | 2002-04-10 | 阿斯特拉曾尼卡有限公司 | 新的化合物 |
US6498161B1 (en) | 1999-04-06 | 2002-12-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6265434B1 (en) | 1999-04-06 | 2001-07-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
AU4143300A (en) | 1999-04-28 | 2000-11-17 | Takeda Chemical Industries Ltd. | Cyclic amide compounds, process for the preparation of the same and uses thereof |
JP2002543126A (ja) | 1999-05-03 | 2002-12-17 | スミスクライン・ビーチャム・コーポレイション | Cxcr−4受容体アンタゴニスト−トロンボポエチン模倣物 |
US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
MXPA01011116A (es) | 1999-05-04 | 2002-06-04 | Schering Corp | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado. |
RU2299206C9 (ru) | 1999-05-04 | 2007-11-20 | Шеринг Корпорейшн | Производные пиперазина, фармацевтические композиции, их содержащие, и применение в качестве антагонистов ccr5 |
ES2246233T3 (es) | 1999-05-04 | 2006-02-16 | Schering Corporation | Derivados de piperidina utiles como antagonistas de ccr5. |
CA2373073A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
WO2000069815A1 (en) | 1999-05-13 | 2000-11-23 | Teijin Limited | Ureido-substituted cyclic amine derivatives and their use as drug |
ES2250132T3 (es) | 1999-05-18 | 2006-04-16 | Teijin Limited | Remedios preventivos para enfermedades asociadas a quimioquinas. |
EP1181310A1 (en) | 1999-05-27 | 2002-02-27 | Celltek Biotechnologies Inc. | Chemokine receptor ccr3 antagonists |
US6165261A (en) | 1999-06-10 | 2000-12-26 | Ergon, Inc. | Water-resistant gypsum composition |
DE60027011T2 (de) | 1999-07-28 | 2006-12-07 | Kirin Beer K.K. | Harnstoffderivate als CCR-3 Rezeptor-Inhibitoren |
SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
JP4831906B2 (ja) | 1999-08-27 | 2011-12-07 | ケモセントリックス, インコーポレイテッド | Cxcr3機能を調節するための複素環式化合物および方法 |
WO2001040227A1 (fr) | 1999-12-03 | 2001-06-07 | Ono Pharmaceutical Co., Ltd. | Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
CA2422013A1 (en) * | 2000-09-14 | 2002-03-21 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
IL156304A0 (en) | 2000-12-11 | 2004-01-04 | Tularik Inc | Cxcr3 antagonists |
GB0100102D0 (en) | 2001-01-03 | 2001-02-14 | Syngenta Participations Ag | Organic compounds |
WO2002074758A2 (en) | 2001-03-16 | 2002-09-26 | Abbott Laboratories | Novel amines as histamine-3 receptor ligands and their therapeutic applications |
MXPA03008529A (es) | 2001-03-19 | 2004-06-30 | Ono Pharmaceutical Co | Derivado de triazaspiro [5.5]undecano y composicion farmaceutica que comprende el mismo como ingrediente activo. |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
EP1381592A1 (en) * | 2001-04-13 | 2004-01-21 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused compounds |
US6495569B1 (en) | 2001-04-19 | 2002-12-17 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
US6720321B2 (en) * | 2001-06-05 | 2004-04-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
JP3829136B2 (ja) | 2001-06-20 | 2006-10-04 | ファイザー・プロダクツ・インク | 新規なスルホン酸誘導体 |
US6867221B2 (en) | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
US20050143372A1 (en) | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
NZ532291A (en) * | 2001-11-14 | 2005-11-25 | Schering Corp | Cannabinoid receptor ligands |
TW200302717A (en) | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
EP1554253A4 (en) | 2002-06-03 | 2006-09-20 | Smithkline Beecham Corp | IMIDAZOLIUM COMPOUNDS INHIBITORS OF CXCR3 |
EP1552842A1 (en) | 2002-06-07 | 2005-07-13 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
JPWO2004026873A1 (ja) | 2002-09-18 | 2006-01-19 | 小野薬品工業株式会社 | トリアザスピロ[5.5]ウンデカン誘導体およびそれらを有効成分とする薬剤 |
US7247725B2 (en) * | 2002-10-30 | 2007-07-24 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
WO2004046110A1 (ja) | 2002-11-15 | 2004-06-03 | Yamanouchi Pharmaceutical Co., Ltd. | メラニン凝集ホルモン受容体拮抗剤 |
WO2004052862A1 (ja) * | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
JP2004256531A (ja) | 2003-02-07 | 2004-09-16 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および用途 |
GB0305426D0 (en) * | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
AU2004233828B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
WO2005023771A1 (ja) * | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | ケモカインレセプターアンタゴニストおよびその医薬用途 |
TWI400232B (zh) | 2004-09-13 | 2013-07-01 | Ono Pharmaceutical Co | 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑 |
JP2007063268A (ja) | 2005-08-05 | 2007-03-15 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
CA2619881A1 (en) | 2005-08-16 | 2007-02-22 | Genzyme Corporation | Chemokine receptor binding compounds |
AU2007225836A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
-
2007
- 2007-03-09 AU AU2007225836A patent/AU2007225836A1/en not_active Abandoned
- 2007-03-09 RU RU2008140144/04A patent/RU2008140144A/ru not_active Application Discontinuation
- 2007-03-09 EP EP07738169A patent/EP1995246A4/en not_active Withdrawn
- 2007-03-09 CA CA002644368A patent/CA2644368A1/en not_active Abandoned
- 2007-03-09 CN CNA2007800167421A patent/CN101443322A/zh active Pending
- 2007-03-09 BR BRPI0708731-4A patent/BRPI0708731A2/pt not_active IP Right Cessation
- 2007-03-09 EA EA200870344A patent/EA200870344A1/ru unknown
- 2007-03-09 WO PCT/JP2007/054684 patent/WO2007105637A1/ja active Application Filing
- 2007-03-09 KR KR1020087024728A patent/KR20090008217A/ko not_active Application Discontinuation
- 2007-03-09 JP JP2008505116A patent/JPWO2007105637A1/ja not_active Withdrawn
- 2007-03-09 MX MX2008011414A patent/MX2008011414A/es not_active Application Discontinuation
- 2007-03-09 US US12/282,464 patent/US8003642B2/en not_active Expired - Fee Related
-
2008
- 2008-09-08 NO NO20083813A patent/NO20083813L/no not_active Application Discontinuation
- 2008-09-09 ZA ZA200807767A patent/ZA200807767B/xx unknown
- 2008-09-29 MA MA31263A patent/MA30294B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0708731A2 (pt) | 2011-06-07 |
US20090131403A1 (en) | 2009-05-21 |
US8003642B2 (en) | 2011-08-23 |
KR20090008217A (ko) | 2009-01-21 |
MX2008011414A (es) | 2008-09-22 |
NO20083813L (no) | 2008-12-10 |
EP1995246A4 (en) | 2010-11-17 |
CN101443322A (zh) | 2009-05-27 |
JPWO2007105637A1 (ja) | 2009-07-30 |
CA2644368A1 (en) | 2007-09-20 |
RU2008140144A (ru) | 2010-04-20 |
AU2007225836A1 (en) | 2007-09-20 |
WO2007105637A1 (ja) | 2007-09-20 |
EP1995246A1 (en) | 2008-11-26 |
MA30294B1 (fr) | 2009-03-02 |
EA200870344A1 (ru) | 2009-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200807767B (en) | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | |
IL192298A (en) | Heterocyclic Compounds, Their Acceptable Salts, Pharmaceuticals Containing and Using Them | |
IL193467A0 (en) | Substituted indazole derivatives, their manufacture and use as pharmaceutical agents | |
IL199397A (en) | Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products | |
IL198411A0 (en) | Haloalkylsulfonanilide derivative or salt thereof, herbicide comprising the derivative as active ingredient, and use of the herbicide | |
EP1932833A4 (en) | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | |
EP1970377A4 (en) | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THIS AS AN ACTIVE SUBSTANCE | |
IL206395A (en) | N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them | |
EP2157093A4 (en) | HETEROCYCLIC PYRROLO-NITROGEN-DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE | |
IL192184A0 (en) | Heterocyclic derivatives and pharmaceutical compositions containing the same | |
IL193274A0 (en) | Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant | |
IL195488A (en) | Compounds, pharmaceuticals containing them and their uses | |
IL188050A (en) | The history of azaindazole, their medicinal preparations and their uses | |
IL177533A (en) | Benzimidazole derivatives, their preparation and pharmaceutical compositions comprising them | |
HK1118016A1 (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
PL1861387T3 (pl) | Pochodne benzoimidazolu i ich kompozycje farmaceutyczne | |
EP2045253A4 (en) | alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient | |
IL206808A (en) | Indolyl-pyridone history, their pharmaceutical preparations and their uses | |
IL193772A0 (en) | 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same | |
PT1861387E (pt) | Derivados de benzimidazol e composições farmacêuticas dos mesmos | |
HK1105202A1 (en) | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient | |
TWI315305B (en) | Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof | |
IL202235A (en) | Amides and thioamides of 2-phenyl-ethyl-amino-acid, their history and their pharmaceutical preparations | |
HK1115315A1 (en) | Tablet containing hardly soluble active ingredient | |
EP1731609A4 (en) | INHIBITOR OF THE EXPRESSION OF RAD51, MEDICAMENT CONTAINING THE INHIBITOR AS ACTIVE INGREDIENT AND USE THEREOF |